The national medicines regulator has intensified its enforcement action against the unlawful manufacture and distribution of unregistered GLP-1 therapies. This development comes as concerns grow over South Africa's rapidly expanding and largely unregulated weight-loss drug market.
The South African Health Products Regulatory Authority (SAHPRA) and the South African Pharmacy Council (SAPC) confirmed they seized several injectable products. The raid took place after a joint inspection at iDexis Compounding, trading as Sentra Pharmacy, in Silverton, Pretoria.
This decisive action comes amid surging global demand for GLP-1 therapies. These medicines mimic a natural hormone that regulates blood sugar levels and appetite. They have become increasingly popular for weight management and are among the fastest-growing segments in the pharmaceutical industry today.
However, SAHPRA has warned healthcare professionals and the public that the targeted unregistered versions pose serious risks to patients. This is particularly true when companies manufacture, import, advertise, or distribute these products outside the country’s official regulatory framework.
Pretoria Pharmacy Accused Of Unlawful Manufacturing
The regulator alleges that the Pretoria pharmacy was manufacturing and distributing unregistered therapies, including semaglutide, tirzepatide and combination formulations. The entities reportedly conducted these activities under the guise of legitimate pharmaceutical compounding.
Officials stated that this operation directly contravened the Medicines and Related Substances Act.
SAHPRA Chief Executive Officer, Dr Boitumelo Semete-Makokotlela, stated that the authority will continue to take firm regulatory and enforcement steps against any entity that violates the law. She emphasised that the unlawful manufacture, importation, advertising and distribution of unregistered medicines pose a serious risk to public health.
According to SAHPRA, inspectors uncovered extensive regulatory failures at the site. These included the illegal importation of active pharmaceutical ingredients (APIs). The facility also failed to conduct proper analytical testing to confirm the quality, potency and purity of the products.
Critical Safety Concerns Under Unregistered GLP-1 Medicines Crackdown
The joint investigation exposed severe deficiencies regarding sterile production. Inspectors allegedly uncovered dust contamination, unsuitable equipment and the absence of a validated heating, ventilation and air-conditioning (HVAC) system, which is mandatory for sterile pharmaceutical production.
Furthermore, the regulator raised concerns about the total absence of a pharmacovigilance system to monitor adverse drug reactions. The authority revealed it has already received reports of adverse events, including hospitalisations, linked to the use of these specific compounded products.
These findings have heightened industry anxieties surrounding the safety of unlawfully produced injections marketed for weight loss. Public interest in semaglutide and tirzepatide continues to break records, making the unregistered GLP-1 medicines crackdown a high priority for local watchdogs.
The Boundaries Of Legitimate Pharmaceutical Compounding
Pharmaceutical compounding is entirely legal under South African law, but it remains subject to strict statutory conditions. It involves preparing customised medicines for individual patients based on a valid prescription from a licensed practitioner.
Crucially, compounding does not give companies the right to manufacture medicines commercially or market unregistered products to the general public. SAHPRA stated that the Pretoria operation had moved far beyond patient-specific compounding. Instead, it had transitioned into large-scale commercial manufacturing and marketing of weight-management drugs.
Enforcement Actions And Imminent Disciplinary Proceedings
Following the site inspection, SAHPRA seized all finished products containing semaglutide, tirzepatide and related combinations found on the premises. The company must now initiate a full recall of all affected products distributed through healthcare providers, pharmacies and other trade channels.
The SAPC confirmed that formal disciplinary action will follow against the pharmacy professionals implicated in the matter. Individuals found selling, compounding or distributing these unregistered items risk severe penalties, including permanent removal from the official pharmacy register.
This regulatory intervention signals a much tougher stance as South Africa grapples with the explosive demand for weight-loss treatments.
Read the Original Article (May require a subscription)